Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015

Vaccine

Volumn 33, Issue 48, 2015, Pages 6684-6688

  Moro, Pedro L ^a   Winiecki, Scott ^b   Lewis, Paige ^a   Shimabukuro, Tom T ^a   Cano, Maria ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse event; Cell culture; Surveillance; Trivalent inactivated influenza vaccine; Vaccine safety

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ARTICLE; BAYES THEOREM; CAUSE OF DEATH; CELL CULTURE; CHILL; DISEASE SURVEILLANCE; FEVER; FLU LIKE SYNDROME; GUILLAIN BARRE SYNDROME; HEADACHE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE REACTION; MAMMAL CELL; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MYALGIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; UNITED STATES; VERTIGO; ADOLESCENT; ADULT; AGED; CELL CULTURE TECHNIQUE; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; INFANT; MALE; MIDDLE AGED; PATHOLOGY; PHARMACEUTICS; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CULTURE TECHNIQUES; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84949789824     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.084     Document Type: Article

References (27)

1. Food and Drug Administration. November 20, 2012 Approval Letter - Flucelvax. Available at: [accessed 23.03.15]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328684.htm.
2. Doroshenko A., Halperin S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009, 8(June (6)):679-688.
3. Centers for Disease Control Prevention (CDC). Prevention and Control of Seasonal Influenza with Vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. MMWR Recomm Rep 2013, 62(September (RR-07)):1-43. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.html [accessed 23.03.15].
4. Grohskopf L.A., Olsen S.J., Sokolow L.Z., Bresee J.S., Cox N.J., Broder K.R., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014, 63(August (32)):691-697. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm [accessed 23.03.15].
5. Food Drug Administration. Flucelvax, Available at: [accessed 23.03.15]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM329134.pdf.
6. Shimabukuro T.T., Nguyen M., Martin D., DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2015, pii:S0264-410X(15)00982-2. [Epub ahead of print].
7. Medical Dictionary for Regulatory Activities. Available at: [accessed 28.04.11]. http://www.meddramsso.com/.
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals. http://www.ich.org/products/meddra.html.
9. Food Drug Administration Postmarketing reporting of adverse experiences. Federal Register 1997, 62:52252-52253. 21 CFR Part 600.80.
10. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5675-5684.
11. Sejvar J.J., Kohl K.S., Gidudu J., Amato A., Bakshi N., Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29:599-612.
12. Brighton Collaboration. https://brightoncollaboration.org/public.
13. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999, 53:177-190.
14. Szarfman A., Machado S.G., O'Neill R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002, 25:381-392.
15. Martin D., Menschik D., Bryant-Genevier M., Ball R. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf 2013, 36(7):547-556. [Epub ahead of print].
16. European Medicines Agency, Optaflu. Available at: [accessed 06.04.15]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000758/WC500046957.pdf.
17. Manini I., Domnich A., Amicizia D., Rossi S., Pozzi T., Gasparini R., et al. Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines 2015, 14(June (6)):789-804.
18. Food Drug Administration. Pharmacovigilance Review Memorandum, August 1, 2912. Office of Biostatistics and Epidemiology/Division of Epidemiology (OBE/DE). Pharmacovigilance Plan Review, Influenza vaccine (cell-culture derived trivalent influenza vaccine, cTIV), formerly Optaflu. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm332467.pdf.
19. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project. Am J Epidemiol 2010, 171:177-188.
20. Institute of Medicine Influenza vaccines Adverse effects of vaccines: evidence and causality 2011, 257-368. The National Academies Press, Washington, DC.
21. Woo E.J. Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System. Clin Infect Dis 2015, 60(March (5)):777-780.
22. Protein Science Corporation, Flublok package insert. Available at: [accessed 06.04.15]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM336020.pdf.
23. Guillain-Barré syndrome and other immune-mediated neuropathies. Chronic inflammatory demyelinating polyneuropathy. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. The McGraw-Hill Companies, Inc.; 2012 [chapter 385].
24. Fenichel G.M. Assessment: neurologic risk of immunization: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999, 52:1546-1552.
25. Kaplan J.E., Katona P., Hurwitz E.S., Schonberger L.B. Guillain-Barré syndrome in the United States, 1979-80 and 1980-81 - lack of an association with influenza vaccination. JAMA 1982, 248:698-700.
26. Lasky T., Terracciano G.J., Magder L., Coski C.L., Ballesteros M., Nash D., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339(25):1797-1802.
27. Baxter R., Bakshi N., Fireman B., Lewis E., Ray P., Vellozzi C., et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis 2013, 57(2):197-204.